focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That Bill Gates has invested in this company or is it a ramp?
Curates egg of an RNS. We are still in belief territory rather than guaranteed income, however, GE Healthcare encouraging and clearly they can sell.
Next 6 - 12 months will tell us a lot.
I'm excited about this and happy to hold.
Gone NT to buy 10000 shares. Free float is tiny
Financial highlights:
· Revenue grew by 47% to £7.6m (2020: £5.2m)
· Operating loss reduced to £4.3m (2020: £4.5m)
· Net cash used in operating activities reduced by 20% to £1.8m (2020: £2.3m)
· Cash and cash equivalents of £5.0m (2020: £8.8m)
Looking forward to results on Tuesday. Again company far too undervalued for their medical simulation systems sold around the globe . Awaiting for he £1 party to finally arrive here
HEIW Invests in NeedleTrainer to Drive Curriculum Changes and Learning Safely
Health Education and Improvement Wales (HEIW) has invested in Intelligent Ultrasound’s (IU) NeedleTrainer. The platform was selected to help drive curriculum changes and provide more learning opportunities for trainees, safely.
A special Health Authority within NHS Wales, HEIW’s responsibilities include postgraduate training of all junior doctors in Wales. Following a significant change to the Royal College of Anaesthetists’ national training curriculum in August 2021, HEIW and the Welsh School of Anaesthesia has moved to address the increased emphasis placed on ultrasound-guided regional anaesthesia (UGRA).
This requirement for UGRA training has increased after training opportunities have been severely restricted over the last two years due to the pandemic and is now a core learning outcome for training.
UGRA is a practical skill which can broadly be split into two parts; acquiring and interpreting an optimal ultrasound image of the relevant sono-anatomy, followed by needle-probe manipulation to maintain visualisation of the needle tip on the ultrasound image as it is advanced to the target where local anaesthetic is deposited.
The first skill can be learnt by performing ultrasound scanning on subjects at courses or local teaching sessions, to identify the anatomy needed in clinical practice. This skill, though more difficult to acquire, is easy to practice in an entirely safe and non-invasive manner. The second skill could not be practiced so easily. However, learning this skill prior to performing needle insertion or an injection on a real patient in a clinical setting has important safety implications.
Sarah Harries, Head of School for Anaesthesia and HEIW Associate Dean, commented “While training and early clinical practice remained safe, as the trainee was always closely supervised, there were risks of needle misplacement leading to nerve damage, pneumothorax, or vascular puncture. We needed a learning solution that would allow trainees to practice and develop this skill prior to injecting a real patient, minimising risks.”
A number of options were considered including the use of cadaveric facilities and phantom models. However, these were limited in scope and fidelity, were expensive and did not provide widespread opportunity for learners across Wales to practise.
NeedleTrainer was selected as it was considered “the most realistic simulated training available”. The only commercially available device which uses augmented reality technology to simulate needle placement on real-time ultrasound, NeedleTrainer provides a spring tipped mock needle which can be pressed onto the skin of a volunteer whilst they are being scanned with an ultrasound machine. The software then superimposes the virtual needle on to the ultrasound image, allowing the learner to practice moving both the needle and probe independently, and advancing the needle safely towar
Hopefully another 50% growth on yearly sales . Still NT to buy in bulk . Might be a big mover next week
Each trade ticks SP up or down . Very small free float…
IUG tweet
Its always busy at our Caerphilly build and distribution facility - March is proving to be busier than ever! Thank you to our new customers for investing in our systems and a big shout out to our Caerphilly team for all their hard work.
Ask now 14.4 p … momentum run underway
Only 40000 shares left at 14p. This stock is clearly tightly held as each trade seems to cause a movement. Volume is non existent but with year results due end of month, it will be interesting to see if the year on year growth has continued.
Taken some more here. With all the AI system works we have an presentations ongoing. SP is far too low again at 13p. Results should show yet another amazing year growth yet IUG continues to be missed and unloved.
When it moves it moves rapidly and free float is minimal… 2022 should be a game changer here
https://www.intelligentultrasound.com/heartworks-ar/
£1662 plus taxes. AI products and simulators keep getting better. Interest here is zero still and again SP is at year low status. Lots of money in bank, lots of clients and amazing products.. just need interest here to arrive one day….
Added few more here today.Still unloved and far to undervalued… one day volume will come
Seems to fluctuate at the moment between 14p and 18p. Needs volume again and another set of decent results to bring interest back here. But also a good one to accumulate around this level. One day it will rocket just needs volume to kick in the momentum
Bit of a worry all the same ,all sells and a lot of them ....hope it's not a sign of bad news ?
So today we have the sells. Hopefully tomorrow will be buying day again
16.44 now for £100 buy. Goes same way for selling…I do think the free float here is very small
Again limit to £100 buy before it goes to NT. would like to know who has been adding or whether there is any free float here at all. Seems to keep jumping again either way on single trades…volume will arrive and this will go vertical (one day)
GE Covid backlog should be clearing now which means ScanNav assist AI’s sales (only £200k at the moment) will start to reflect global rollout under GE Healthcare. ScanNav is rolled out as a package in all new (once it clears old stock) ultrasound machines GE sells. GE healthcare has $18bn revenue (out of GE’s total revenue of $70bn). The company said that it expects AI revenue to accelerate in 2022 and that is obvious in context of GE. Sales and marketing has been up to GE so far but that also means IUG doesn’t have to pay for sales and marketing to GE’s gigantic customer base ..
As per last results. Appears IUG are moving more into real time support as well. The AI division started and estimates the revenue to begin with the licence agreements with GE Healthcare
RNS snippets -Revenue relating to the Group's Clinical AI Division is expected to be £0.2m (2020: £0.0m). These first AI related products provide real-time support to?clinicians whilst they are scanning and include the ScanNav Assist obstetric AI software that is utilised by GE Healthcare as SonoLyst on their Voluson SWIFT ultrasound machine; the CE approved ScanNav Anatomy Peripheral Nerve Block (PNB) regional anaesthesia highlighting device and NeedleTrainer that incorporates the PNB software to teach ultrasound-guided needling skills.
The Group remains confident that the expected increase in face-to-face medical exhibitions and congresses, that are fundamental to the launch process of the Group's new products, and the continued roll-out of ScanNav Assist and PNB will accelerate AI revenue growth in 2022. The need for an additional US-based Human Factors study has pushed the regulatory approval and anticipated launch of the PNB clinical system in the US to the summer, but the Group still envisages the PNB system will contribute to US revenues in 2022.
They have also been in Los Angeles demonstrating the AI products last week.
So in all, with all the various training AI systems, Real Time emerging systems, links with majors GE Healthcare, Boston Scientific (more here) https://www.intelligentultrasound.com/about-us/ then I feel the re rate is beginning to finally get underway. Covid allowed even IUG to make Covid AI training systems but prevented exhibitions and classroom based learning.
Do I feel this share can reach £1 - yes certainly, this year or next year maybe even so .....
Cannot buy £1000 now without going to NT. still moving up each time on trades. 20p hopefully within few weeks
The AI products Scan Nav etc are licensed and as such there are return subscriptions . It seems we’re are moving into the Neo natal field as well. From what I understand Covid, slowed much of the presentations sales activities down as a lot harder to demonstrate products. However when you look at some of the clients NHS, New York hospitals etc then it is not a one trick pony. Very undervalued in my opinion with small free float. Momentum seems to be the best catalyst for a rise at the moment pending their exhibitions taking off again which they are
"Glad to have invested at what looks like great value will add further as I understand more about the company." Totally agree , nice and steady , no mass piling in and out...
Glad to have invested at what looks like great value will add further as I understand more about the company.
Like most on aim, looking for multi-bagger in short to medium term (1 to 3 years)
What do folks think will be the next indicator / driver for a re-rate?
Thanks O4L
Been some nice loading up here last few days…Looking good for return over 15p again